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ABSTRACT (250 words, maximum of 250 words) 
Context: Discontinuation of denosumab leads to a rapid reversal of its therapeutic effect. However, 
there are no data regarding how unintended delays or missed injections of denosumab impact bone 
mineral density (BMD) response.  
Objective: We examined the association of delays in injections of denosumab with BMD change.  
Design: We used electronic medical records from two academic hospitals from 2010 to 2017.  
Participants: Patients over 45 years of age and used at least two doses of 60mg denosumab. 
Denosumab adherence was evaluated by the medication coverage ratio (MCR). Good adherence 
corresponds to a dosing interval 7 months (defined by MCR 93%), moderate adherence 
corresponds to an interval of 7-10 months (MCR 75-93%), and poor adherence corresponds to an 
interval 10 months (MCR 74%).  
Outcome Measures: Annualized percent BMD change from baseline at the lumbar spine, total hip, 
and femoral neck.  
Results: We identified 938 denosumab injections among 151 patients; the mean (SD) age was 69 
(10) years, and 95% were female. Patients with good adherence had an annualized BMD increase of 
3.9% at the lumbar spine, compared with patients with moderate (3.0%) or poor adherence (1.4%, p 
for trend 0.002). Patients with good adherence had an annualized BMD increase of 2.1% at the total 
hip, compared with patients with moderate (1.3%) or poor adherence (0.6%, p for trend 0.002).  
Conclusions: A longer interval between denosumab injections is associated with suboptimal BMD 
response at both spine and total hip. Strategies to improve the timely administration of denosumab 
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Denosumab is an effective anti-resorptive drug commonly prescribed for the treatment of 
osteoporosis. It is a fully-humanized monoclonal antibody that binds to the receptor activator of the 
nuclear factor-κB ligand with high specificity and affinity, thereby impairing osteoclast function and 
inhibiting bone resorption(1). A large phase 3 randomized, placebo-controlled trial showed that 
denosumab 60 mg every six months significantly increased bone mineral density (BMD) over 24 
months (2), and was associated with reduced vertebral, nonvertebral, and hip fractures at 36 
months (3). A long-term extension trial showed that denosumab injections for up to 10 years was 
associated with low fracture incidence and sustained BMD increase without an obvious plateau(4). 
Unlike bisphosphonates, discontinuation of denosumab leads to rapid reversal of its therapeutic 
effect(5); bone turnover rebounds above baseline levels three months after discontinuation(2), and 
BMD gained in the prior two years is reduced to baseline levels after one year without follow-on 
anti-osteoporosis treatment(2,6). Discontinuing denosumab also exposes patients to an increased 
risk of multiple vertebral fractures, particularly in patients with prior vertebral fractures (7–11). 
These fractures often occur within a very short off-treatment period (2 to 10 months after the 
denosumab therapeutic-effect has waned or 8-16 months from the last denosumab injection)(7), 
highlighting the importance of timely administration(7,12).  
Although delaying or omitting denosumab doses is theoretically associated with unfavorable BMD 
response and increased fragility fracture risk, data from typical clinical practice are lacking. Previous 
studies mostly focused on the risk factors(13) and rate of denosumab discontinuation(13–17), which 
was 49% at 12 months and 64% at 24 months(14). In a European study, adherence (defined as < 7 
months between two consecutive injections) was 83–89 % at 12 months and 63–70% at 24 
months(13,15). While there is ample evidence that adherence to six-monthly dosing wanes, the 
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A randomized controlled trial (RCT) is the gold standard for evaluating the efficacy of interventions. 
However, an RCT is not feasible in the case of denosumab dosing delay. An observational approach, 
which takes advantage of naturally occurring variations in the timing of denosumab administration, 
allows us to examine its impact on BMD response in routine clinical settings. In this study, we aim to 




The Partners HealthCare electronic medical record (EMR) is used by several hospitals, including the 
Brigham and Women’s Hospital and Massachusetts General Hospital. We used medical records of 
patients who took denosumab for the treatment of osteoporosis from October 2010 to December 
2017.  We first identified new users of denosumab who had been treated with this medication for at 
least 1 year (2 or more denosumab injections records). New users of denosumab and the date of 
injections were then verified by manual review of medical records. 
Patients over 45 years of age and had at least two dual-energy X-ray absorptiometry (DXA) scans in 
the EMR system were included. The following exclusion criteria were then applied: a history of 
Paget’s disease; simultaneous use of teriparatide, oral or intravenous bisphosphonates; and high-
dosage denosumab (120 mg/ month) prescribed for cancer patients. The Partners HealthCare 
Institutional Review Board approved all aspects of this study (2017P001614). 
Outcomes and study design 
We adopted a repeated measures design to examine the impact of denosumab delays on BMD. Each 
subject may contribute to the analysis multiple times, depending on how many follow-up DXA tests 
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began after the index date and ended at any of the following events: switch to another anti-
osteoporosis drug (bisphosphonates, teriparatide, or raloxifene), 9 months after the last dose, or the 
end of this study (December 31, 2017). Follow-up time for each patient was divided into a series of 
periods between each repeated DXA scan. We first defined a baseline DXA test window (2 years 
before and 3 months after the index date) and a follow-up DXA test window (6 months after index 
date to the last injection date plus 9 months) to identify baseline DXA and follow-up DXA. For 
patients with multiple DXAs within the baseline window, the scan closest to the index date was 
chosen as baseline DXA. Similarly, for patients with multiple DXAs within the follow-up window, the 
one closest to the end of the last dose’s therapeutic effect (last dose plus 6 months) was chosen as 
the final DXA. Follow-up time was divided into a series of periods divided by two sequential DXA 
examinations (Supplement 1)(19); exposure (medication coverage ratio, MCR) and outcome (BMD 
change) were calculated for each period. The outcome of interest was annualized percent BMD 
change from baseline at the lumbar spine, total hip, and femoral neck (Supplement 1)(19). We used 
BMD (g/cm2) from routine DXA scans (QDR 4500/4500A; Hologic, Bedford, MA) of the 
posteroanterior lumbar spine, total hip, and femoral neck. 
Evaluation of denosumab adherence 
We defined appropriate adherence as less than 7 months between two consecutive denosumab 
injections (16,17), which corresponds to a delay of <1 month for the subsequent dose. This definition 
is based on the known rapid reversibility of the suppression of bone resorption when denosumab is 
discontinued (15). Medication coverage ratio (MCR) was defined to quantitatively examine the 
association between the denosumab dosing interval and outcomes(13,15). The MCR measures the 
percentage of days that a patient was covered over a given time interval after receiving 
denosumab(20). We used the MCR as the parameter to define the study groups. Good MCR (93%) 
corresponds to a dosing interval 7 months,  moderate MCR (75-93%) corresponds to 7-10 months, 
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injection of denosumab provides 180 days of therapeutic coverage and the effect of denosumab 
wanes after this period. We calculated the MCR in each interval between two DXA examinations. 
This approach can reflect the clinical situation that adherence may change over time.  Sensitivity 
analysis was conducted using an alternative measure of denosumab delay, medication possession 
ratio (MPR), which additionally accounts for dosing before 6 months has elapsed (See supplement 2 
for the illustration of the difference between MCR and MPR)(21). The dosage and date of each 
denosumab injection were verified by review of the medical record by one author (HL).  
Covariate assessment 
Patient characteristics were collected from the EMR. Variables of interest included age (at the index 
date), gender, race, body mass index (BMI), other medications of interest (hormone replacement 
therapy, raloxifene, glucocorticoids), and comorbidities (22). BMI was assessed based on the most 
recent value within a year prior to the index date. Comorbidities were defined using corresponding 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), or ICD-10-
CM codes. We also collected information on bisphosphonate treatment duration and fragility 
fractures(23) occurring in the year before the index date.  
Prior use of other anti-osteoporosis medications (alendronate, ibandronate, risedronate, zoledronic 
acid, and teriparatide) was verified by chart review and recorded. We classified drug brand or 
generic names into four categories, oral bisphosphonates (alendronate 10 mg/ day, or 70 mg/ week, 
ibandronate 150 mg/ month, risedronate 35 mg/ week), intravenous bisphosphonate (zoledronic 
acid 5 mg/ year or 2.5 mg/ 6 months, ibandronate 3 mg every 3 months, pamidronate 60 mg every 6 
months or 30 mg every 3 months) and teriparatide (20 g/ day percutaneous) for each patient. The 










/dgz321/5693392 by Endocrine Society M
em














Continuous variables were expressed as mean  SD or median (interquartile range, IQR) when 
appropriate. Categorical variables were expressed as frequency and percentage. We described 
chronological adherence up to the 10th denosumab injection; that is, the proportion of patients who 
received the 2nd injection without delay, the proportion who received all injections up to the 3rd 
without delay, up to the 4th, 5th, etc. We then examined the association between MCR and 
annualized BMD change at the lumbar spine, total hip, and femoral neck. Since we performed the 
study at the subject-period level and one subject may contribute response data multiple times, we 
used generalized estimating equations (GEE) to analyze this correlated data. The robust sandwich 
estimate of the standard error was reported (24). Each observation (at subject-period level) was 
categorized into one of the three groups: poor (MCR 74%; corresponding to an interval of 10 
months between two doses), moderate (MCR 75-93%; 7-10 months between two doses) and good 
(MCR 93%; within 7 months between two doses) based on the MCR calculated in each period. The 
poor adherence category served as the reference group. The models were adjusted for age, gender, 
BMI, rheumatoid arthritis,  prior fragility fractures, prior alendronate, prior ibandronate, prior 
risedronate, prior intravenous bisphosphonate, prior bisphosphonates treatment length (months), 
prior anabolic treatment, prior glucocorticoid, length of the follow-up period, and the number of 
denosumab injections previously received. 
Additionally, we performed a post hoc stratified analysis to exam the effect of timing of the dose 
delays (first 2 years vs. after 2 years of the therapy). We further examined interactions between 
MCR and other selected covariates (e.g., baseline BMD and cumulative denosumab duration). To aid 
interpretability, we used percentage change in BMD from baseline over each follow-up 
intervals(3,25–28). Annualized BMD increase was used to account for the different interval lengths. 
Predicted annualized BMD increases (average marginal means) in each category from multivariable 
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In addition, six sensitivity analyses were performed for the primary GEE analyses. First, to more 
accurately capture the baseline BMD, we repeated the analyses using a strict baseline DXA window 
(less than 1 year prior to the index date). Second, given the fact the prior anabolic treatment may 
potentially lead to different BMD response to follow-up anti-resorptive agents, we repeated the 
analysis by excluding patients who received teriparatide before denosumab. Third, we restricted the 
analysis to female patients. Fourth, we excluded patients who received denosumab for <24 months 
to evaluate the long-term association of MCR and BMD changes. Fifth, given the concern that the 
rebound effect may be different between early time points (i.e., 1-4 months) and late time points 
(i.e., 12-24 months), we excluded observations with an off-treatment period > 12 months. Sixth, we 
repeated the analyses using MPR as an alternative measure of denosumab delay. Data were 
analyzed in the statistical environment R-3.5.0 (https://cran.r-project.org). 
RESULTS 
Patient demographics and baseline characteristics 
We identified 151 patients who received at least two doses of denosumab, amounting to a total of 
938 denosumab injections, between October 1, 2010, and December 31, 2017 (Figure 1). The mean 
(SD) age at index date was 69 (10) years, with 31% of patients being <65 years of age, 42% between 
65 and 75 years, and 26% >75 years. The majority of patients were female (95%). 35% had a history 
of fragility fracture, 87% had a history of bisphosphonate-use, the average prior bisphosphate 
duration was 73 months, and 19% completed 2 years of prior teriparatide treatment (Table 1). 
Denosumab adherence 
Among 151 patients, the overall median (IQR) follow-up was 37 (28, 55) months. These patients 
received an average of six doses of denosumab; 15% received 2 to 3 doses, 62% received 4 to 8 
doses, and 23% received over 8 doses. Overall, 21% of all administered denosumab injections were 
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injection and dropped to 13% after 8th injection and 8% after 10th injection. 97% of patients received 
the next injection within 10 months for the 2nd dose, but only 40% did so after 10th injection, 
suggesting 60% patients would have at least one injected delayed for over 4 months at year 5 (Figure 
2).  
Two hundred and thirty-three follow-up DXA tests were identified from 151 patients, resulting in 
233 short follow-up periods. The average length of these short follow-up periods was 21 months. 
MCR was calculated during each period and then used as a parameter for to group observations into 
good, moderate, poor adherence groups. The overall median MCR (IQR) calculated in each follow-up 
interval was 89% (85%, 97%), with 64% (49%, 71%) for poor adherence, 86% (83%, 90%) for 
moderate adherence, and 97% (96%, 99%) for good adherence group. The distribution of MCR is 
shown in Supplement 3(29).  
Association between MCR and BMD response  
Among all study subjects, unadjusted annualized percentage change in BMD was 2.7% (95% CI, 2.3 
to 3.1%) at the lumbar spine, 1.2% (95% CI, 1.0 to 1.5%) at the total hip, and 1.1% (95% CI, 0.8 to 
1.3%) at the femoral neck. Within the groups (poor, moderate and good adherence), unadjusted 
annualized change in BMD was 1.4%, 3.0% and 3.9%, respectively at the lumbar spine (p for trend = 
0.002), and 0.6%, 1.3% and 2.1% respectively at the total hip (p for trend = 0.001). Annualized BMD 
change was not significantly different at the femoral neck across three groups: 1.3% poor, 1.5% 
moderate, and 1.7% good (p for trend = 0.49) (Table 2). Pairwise comparison showed that 
annualized BMD changes in good and moderate adherence groups were greater than those in poor 
adherence groups at both lumbar spine and total hip, but no significant difference of BMD changes 
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In the final model adjusting for age, gender, BMI, rheumatoid arthritis, fragility fracture history,  
bisphosphonates history and duration, anabolic treatment history, glucocorticoid history, follow-up 
length and the number of denosumab injections previously received, annualized change in lumbar 
spine BMD was higher among subjects with good adherence (3.9%) than moderate adherence (3.0%) 
or poor adherence (1.4%) (p for trend 0.002). A similar trend was observed for total hip BMD (2.1% 
vs. 1.3% vs. 0.6%, p for trend = 0.002, Table 2). Femoral neck BMD changes were not associated with 
adherence (p for trend = 0.487).  Pairwise comparisons from the adjusted model were similar to 
those from unadjusted models, differences in the annualized BMD increase at the total hip between 
the moderate adherence group and the poor group did not reach statistical significance (0.8%, 
95%CI, -0.1 to 1.7%) (Supplement 4)(30). 
In the multivariable model with a continuous measure for MCR, MCR was statistically significantly 
associated with annualized BMD changes at both the lumbar spine and total hip areas, but not for 
BMD changes at the femoral neck. In a post hoc stratified analysis, we compared the effect of delays 
during the first 2 years (first 4 doses) vs. after 2 years (5th or subsequent doses) (Table 3). The 
annualized BMD increase in the poor adherence group was consistently less than the moderate and 
good adherence groups, but all BMD increases were less dramatic in later years. 
In the poor adherence group, the annualized BMD increase was 2.9% at the lumbar spine and 1.0% 
at the total hip during the first 2 years’ treatment, while beyond 2 years, the increases were quite 
small, with only 0.1% at the lumbar spine and 0.1% at the total hip. But our study was underpowered 
to detect this effect modification; interactions between MCR and therapy length were not 
statistically significant. Effect size estimates from sensitivity analyses were consistent with the 
primary analysis (Figure 3). Since the BMD percentage scale might be influenced by the baseline 
chosen, we also repeated the same analysis with absolute BMD (g/cm2); results were similar 
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In this study, we showed that adherence with denosumab injections over 3 to 5 years was 
suboptimal, and almost half of the study population experienced at least one injection-delay of over 
four months through 4 years. Our study demonstrates that longer intervals between denosumab 
administrations are associated with suboptimal BMD response at the total hip and lumbar spine. 
These results highlight the importance of timely denosumab administration when using this drug for 
long-term osteoporosis management.  
 
An important observation of the current study is that adherence beyond 24 months declined 
dramatically, with proportions of adherent patients as low as 28% at 36 months, 13% at 48 months, 
and 8% at 60 months. A more disturbing finding is that a large proportion of the study population 
experienced at least one delay of over four months: as high as 27% at 36 months, 44% at 48 months, 
and 63% at 60 months. Given the observed difference in BMD increase among patients who received 
denosumab on schedule and those with >7 months between doses, these patients are likely at 
higher risk for suboptimal BMD improvements, or even decreases, during the off-treatment period.  
Interventions aimed at improving long-term adherence to denosumab should be implemented to 
achieve better treatment outcomes.  
 
The consequences of the delays mentioned above were not well examined in previous studies. A 
prior study showed that the BMD responses did not differ significantly at one year among patients 
who received subsequent injection less than 5 months, between 5 and 7 months, or greater than 7 
months after initial injection (18).  However, the results of the current study showed that adherence 
was consistently associated with less robust improvements in annualized BMD response at both the 
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Our study had longer follow-up with median 3 years and up to 5 years, evaluated adherence using 
time-varying MCR, and compared the BMD changes between the good (corresponding subsequent 
injection between 5 and 7 months) and poor adherence (corresponding subsequent injection greater 
than 10 months). Together, these factors gave us higher statistical power to detect differences in 
BMD change between patients with good and poor adherence. In previous randomized controlled 
trials, lumbar spine BMD increased by 3.2 to 6.7% and total hip BMD by 1.9 to 3.6% at 12 
months(31). Although the estimated annualized BMD increase cannot be directly compared with 
that from trials, the low BMD response from the poor adherence group in contract to good 
adherence group suggests the effect of denosumab in poorly adherent populations were not fully 
achieved. A recent study by Bouxsein et al showed that greater improvements in BMD were strongly 
associated with greater reductions in vertebral and hip fractures(32): for a 2% improvement in total 
hip BMD, we might expect a 28% reduction in vertebral and 16% reduction in hip fracture risk. In the 
current study, we found a difference of 2.5% annualized BMD increase at the lumbar spine and 1.5% 
at total hip between adherent patients and non-adherent patients. These effect sizes may translate 
into considerable differences in fracture risk, but limitations of surrogate outcomes are well known, 
and further studies using fracture outcomes are needed.  
 
In a post hoc stratified analysis, we checked whether the effect of delays was different between the 
early and later years of denosumab therapy. The annualized BMD increase in the poor adherence 
group was consistently less than moderate and good adherence groups, but all BMD increases were 
less in later years. In the poor adherence group, the annualized BMD increase was 2.9% at the 
lumbar spine and 1.0% at the total hip during the first 2 years treatment; beyond 2 years, the 
increases were quite small, with only 0.1% at the lumbar spine and 0.1% at the total hip. Delay might 
have a large effect in the later years than the early years, that is, rebound effects may be more 
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interaction between delay and treatment duration. Studies using bone turnover markers or 
histomorphometric measurements may shed further light on this phenomenon.  
In our study, the BMD response at the femoral neck was not sensitive to lower adherence, which 
deserves further discussion. One possible explanation is that BMD measurement at the femoral neck 
has much greater variability than that at the lumbar spine or total hip relative to the magnitude of 
BMD gains at each site, and thus may require a larger sample size to achieve statistical difference 
across MCR groups. Another hypothesis is that trabecular bone may be more vulnerable to 
intermittent bone resorption than cortical bone. Vertebral bone is up to 80-90% trabecular(33,34), 
the hip is about 60% trabecular(34) and at the femoral neck cortical bone prevails with only 25% 
being trabecular(33). The BMD change of trabecular bone might be the main contributor of BMD 
change difference across different MCR groups. As the femoral neck has relatively fewer trabecular, 
a much large sample size is needed to detect the difference across MCR groups. Future studies are 
needed to confirm these hypotheses. 
 
Our study has several strengths. First, the longitudinal data allow us to quantitatively examine the 
impact of interventions that are difficult or unethical to experimentally manipulate. Using 
longitudinal DXA tests, both dosing delay and BMD changes can be accurately evaluated. Second, as 
denosumab is a long-acting agent, the gaps between injections can be accurately defined by MCR. 
We adopted a repeated measures design and measured MCR for each patient in a series of intervals 
to increase statistical power. Finally, our follow-up period was much longer than previous studies; 
the majority of existing studies have a follow-up duration of 1 to 2 years. Long-term assessment of 
denosumab adherence and its association with treatment outcomes, such as BMD, is an essential 
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There were also limitations. We defined the baseline DXA using a relatively wide window (2 years 
before and 3 months after the first denosumab injection), but sensitivity analysis using a narrower 
window (1 year before and 3 months after the first injection) showed similar results. We required 
patients to have both a baseline and at least one follow-up DXA; this results in selection bias. A 
comparison of baseline characteristics showed that the included patients were younger and less 
frequently had fragility fractures compared to the excluded patients (Supplement 5)(35). Thus, 
results from the current study might underestimate the association between dosing delay and BMD 
response.  In this study, we pooled the longitudinal BMD results from the DXA reports and cannot 
guarantee that these DXA tests were performed under exactly the same settings, but it is not likely 
to significantly change measurements since clinicians used these longitudinal BMDs to guide clinical 
decision making. Both MCR and MPR provide are good methods to examine the injection delay, but 
it requires an additional assumption. We assume that the off-treatment effect observed in serial 
follow-up intervals is similar and additive when the duration of the off-treatment period increases. 
Based on the pharmacodynamic profile of denosumab that the therapeutic-effect wanes quickly 
when discontinued, this is a reasonable but nevertheless strong assumption. In this study, we used 
annualized BMD change, which can be a helpful outcome for comparing BMD response across study 
groups. Since BMD increase is not linear, the magnitude of annualized BMD changes should not be 
viewed the same as the yearly BMD changes from trials, thus limiting the extrapolation of these 
estimates. Finally, we did not evaluate the difference in fracture endpoints due to low fracture 
incidence in the study cohort. Future studies with fracture endpoints are needed to confirm our 
results. 
Conclusion and clinical implications 
In conclusion, long-term adherence to denosumab was suboptimal in this routine clinical population. 
Better adherence was associated with greater annualized BMD response at both the lumbar spine 
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delay. Since denosumab administration requires an appointment with the health care system, delays 
may be unavoidable in routine clinical practice. Currently, little evidence exists regarding how long a 
delay must be avoided. Our results provide evidence that a delay of over four months (i.e.,>10 
months between doses) may be unacceptable, but future studies are needed to determine the exact 
threshold. Determining effective strategies to improve adherence with denosumab, and 
implementing those strategies, are crucial if we are to optimize the therapeutic benefits of this 
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Figure 1 Study population 
Figure 2 Adherence of denosumab from 2nd to 10th injections Adherence was examined using 
different adherence window (30 days and 120 days), chronological adherence was high at 2nd 
injection, but dropped dramatically. 
 
Figure 3 Results of sensitivity analyses.  
Comparisons between primary analysis and six sensitivity analyses for BMD increase at the lumbar 
spine, total hip, and femoral neck. Primary result: Annualized BMD changes of the three study 
groups from the primary analyses; Use 1-year baseline window: repeat the analyses using a strict 
baseline DXA window (less than 1 year prior to the index date); No prior teriparatide: repeat the 
analysis by excluding patients who received teriparatide before denosumab; Females only: restrict 
the analyses to female patients; DMAb over 24 months: excluded patients who received denosumab 
for <24 months; Alternative measurement MPR: repeat the analyses using MPR; and Off-treatment 
period within 12 months: exclude observations with an off-treatment period > 12 months.  
The sensitivity analyses were adjusted for age, gender, BMI, rheumatoid arthritis (Yes/No), prior 
fragility fractures (Yes/No), prior alendronate (Yes/No), prior ibandronate (Yes/No), prior risedronate 
(Yes/No), intravenous bisphosphonate (Yes/No), prior bisphosphonates treatment length (months), 
prior anabolic treatment (Yes/No), prior glucocorticoid (Yes/No), length of follow-up period, and the 
number of denosumab injections previously received;  
p value is from a trend test of an ordered relationship across the three groups (poor, moderate and 
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N a 31 67 135   
Demographics 
    
Age, mean (SD), years 67 (11) 69 (11) 69 (10) 0.520 
Female, % 31 (100.0) 62 ( 92.5) 129 ( 95.6) 0.262 
BMI, mean (SD), kg/m2 23.99 (4.03) 24.34 (5.03) 23.58 (3.84) 0.478 
Comorbidities, % 
    
Hyperthyroidism     1 (  3.2)      8 ( 11.9)     11 (  8.1)  0.345 
Esophagus disease    17 ( 54.8)     36 ( 53.7)     64 ( 47.4)  0.600 
Hypertension    15 ( 48.4)     42 ( 62.7)     75 ( 55.6)  0.383 
Myocardial infarction     1 (  3.2)      1 (  1.5)      7 (  5.2)  0.431 
Peripheral vascular disease     0 (  0.0)      4 (  6.0)     13 (  9.6)  0.157 
Chronic pulmonary disease    15 ( 48.4)     22 ( 32.8)     53 ( 39.3)  0.330 
Diabetes     6 ( 19.4)     13 ( 19.4)     27 ( 20.0)  0.993 
Peptic ulcer disease     3 (  9.7)      4 (  6.0)      3 (  2.2)  0.132 
Chronic kidney diseases     7 ( 22.6)     13 ( 19.4)     29 ( 21.5)  0.919 
Rheumatoid arthritis     1 (  3.2)      6 (  9.0)      9 (  6.7)  0.575 
Osteoarthritis    21 ( 67.7)     39 ( 58.2)     79 ( 58.5)  0.615 
Any cancer    17 ( 54.8)     25 ( 37.3)     66 ( 48.9)  0.178 
CCI Index (median [IQR])  3 [2, 6]  2 [0, 5]  2 [0, 5] 0.137 
Baseline BMD, mean (SD), g/cm2 
    
Lumbar spine  0.81 (0.11)  0.78 (0.11)  0.78 (0.10) 0.403 
Total hip  0.74 (0.07)  0.70 (0.11)  0.72 (0.08) 0.109 
Femoral neck  0.60 (0.07)  0.58 (0.09)  0.59 (0.08) 0.551 
Prior fracture, % 
    
Fragility fracture    12 ( 38.7)     22 ( 32.8)     46 ( 34.1)  0.846 
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Spine fracture     4 ( 12.9)     11 ( 16.4)     25 ( 18.5)  0.742 
Medications, ever use, % 
    
Alendronate    20 ( 64.5)     47 ( 70.1)     88 ( 65.2)  0.756 
Ibandronate     1 (  3.2)      4 (  6.0)     12 (  8.9)  0.487 
Risedronate     5 ( 16.1)      7 ( 10.4)     18 ( 13.3)  0.715 
IV bisphosphonate     9 ( 29.0)     22 ( 32.8)     43 ( 31.9)  0.931 
BP length, mean (SD),  months 66 (48) 71(50) 74 (51) 0.725 
Teriparatide     6 ( 19.4)     13 ( 19.4)     32 ( 23.7)  0.734 
Systemic corticosteroids    22 ( 71.0)     41 ( 61.2)     78 ( 57.8)  0.396 
Hormone replacement therapy    20 ( 64.5)     26 ( 38.8)     52 ( 38.5)  0.025 
Raloxifene     6 ( 19.4)      3 (  4.5)     24 ( 17.8)  0.026 
Labs 
    
Serum Vit D, mean (SD), ng/mL 42.97 (15.88) 40.33 (12.01) 45.11 (14.60) 0.078 
Serum Ca2+, mean (SD), mg/dL  9.52 (0.36)  9.63 (0.42)  9.68 (0.50) 0.226 
Serum creatinine, mean (SD), mg/dL  0.92 (0.39)  0.99 (0.47)  0.98 (0.40) 0.790 
eGFR, mean (SD),  mL/min/1.73 m² 54.48 (11.25) 52.79 (11.95) 53.50 (11.73) 0.797 
 
a N was calculated at an observational level; each individual may contribute to different adherence groups 
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Table 2. Annualized percentage change in BMD across three groups 
 
Models 
Annualized BMD increase from baseline % a (95%CI) 







    
 Lumbar spine 1.4 (0.3, 2.5) 3.0 (2.3, 3.7) 3.9 (3.0, 4.8) 0.002 
 Total hip 0.6 (-0.2, 1.3) 1.3 (1.0, 1.7) 2.1 (1.6, 2.6) 0.001 
 Femoral Neck 1.3 (0.3, 2.3) 1.5 (0.9, 2.0) 1.7 (0.9, 2.6) 0.491 
 Adjusted b 
     
Lumbar spine 1.4 (0.5, 2.3) 3.0 (2.3, 3.6) 3.9 (3.1, 4.7) 0.002 
 
Total hip 0.6 (-0.2, 1.3) 1.3 (1.0, 1.6) 2.1 (1.6, 2.6) 0.002 
 
Femoral Neck 1.3 (0.2, 2.3) 1.5 (0.9, 2.0) 1.7 (0.9, 2.6) 0.487 
 
      a We performed the study at the subject-period level, and one subject may contribute response data 
multiple times. The average marginal means were used. The average marginal effect means are the 
average fitted values of the annualized percentage change in BMD for each of the three categories from 
the regression model. MCR, medicine coverage ratio.  
b Adjusted for age, gender, BMI, rheumatoid arthritis (Yes/No), prior fragility fractures (Yes/No), prior 
alendronate (Yes/No), prior ibandronate (Yes/No), prior risedronate (Yes/No), intravenous 
bisphosphonate (Yes/No), prior bisphosphonates treatment length (months), prior anabolic treatment 
(Yes/No), prior glucocorticoid (Yes/No), length of follow-up period, and the number of denosumab 
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Table 3 Delayed effect on annualized BMD increase in the early years versus later years. 
 
 
Adjusted models b 






MCR (>93%)  
In the early years (cumulative DMAb  4 doses) 
  
Lumbar spine 2.9 (1.6, 4.2) 3.2 (2.3, 4.2) 4.4 (3.3, 5.4) 0.100 
Total hip 1.0 (-0.1, 2.1) 1.7 (1.3, 2.2) 2.6 (1.9, 3.2) 0.003 
Femoral Neck 2.5 (1.0, 4.0) 1.9 (1.2, 2.6) 2.2 (1.1, 3.3) 0.716 
In later years (cumulative DMAb  5 doses) 
   
Lumbar spine 0.1 (-0.8, 1.0) 2.6 (1.8, 3.3) 2.4 (1.7, 3.1) 0.004 
Total hip 0.1 (-0.7, 1.0) 0.7 (0.3, 1.2) 0.8 (0.5, 1.2) 0.157 
Femoral Neck 0.05 (-0.8, 0.9) 0.7 (-0.2, 1.6) 0.6 (-0.04, 1.2) 0.558 
     a The average marginal means were used.  
 
b Adjusted by age, gender, BMI, rheumatoid arthritis (Yes/No), prior fragility fractures (Yes/No), prior 
alendronate (Yes/No), prior ibandronate (Yes/No), prior risedronate (Yes/No), intravenous 
bisphosphonate (Yes/No), prior bisphosphonates treatment length (months), prior anabolic treatment 
(Yes/No), prior glucocorticoid (Yes/No), length of follow-up period, and the number of denosumab 
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